Hodgkin's Disease and Chemotherapy Before 40 Years
Launched by LILLE CATHOLIC UNIVERSITY · Oct 31, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how treatment for Hodgkin's Disease affects thinking and memory in patients aged 18 to 40. Researchers want to find out how common these thinking problems are after chemotherapy and/or radiation therapy, and how they relate to feelings of anxiety or depression. To do this, they will compare patients with Hodgkin's Disease to healthy individuals of similar ages and education levels. By using brain scans (MRI) and tests to assess memory and attention, the study aims to gain insights into these issues and improve care for patients.
To participate in this trial, patients must be newly diagnosed with Hodgkin's Disease and plan to receive treatment. They need to be fluent in French and able to complete cognitive assessments. Healthy participants must also be aged 18 to 40 and speak French. Both groups must agree to join the study and be registered with social security. Importantly, individuals with certain medical histories, such as previous chemotherapy or severe mental health issues, will not be eligible. Participants can expect thorough evaluations and support throughout the study, contributing valuable information to enhance treatment and quality of life for young adults facing Hodgkin's Disease.
Gender
ALL
Eligibility criteria
- Inclusion criteria - case :
- • Patient with newly diagnosed Hodgkin's disease
- • With intention to treat with chemotherapy +/- radiotherapy
- • Aged between 18 and 40 years
- • Fluency in French
- • Able to undergo neuropsychological evaluation (absence of major sensory disorders)
- • Agreeing to take part in the study and having signed the informed consent form
- • Affiliated with a social security scheme
- Inclusion criteria - controls:
- • Individual without Hodgkin's disease
- • Aged between 18 and 40
- • Proficient in French
- • Agreeing to participate in the study and having signed the informed consent form
- • Affiliated with a social security scheme
- • Cases and controls will be matched on age (± 5 years difference), and number of years of education (difference ≤ 2 years).
- Non-inclusion criteria - cases + controls :
- • Claustrophobia preventing MRI from being performed
- • Contraindication to MRI
- • Previous chemotherapy
- • History of neurological or psychiatric illness, including severe depression, or cognitive impairment
- • Use of medications that may cause neurological or psychiatric signs
- • Alcohol or drug abuse
- • Pregnant women
- • Persons under guardianship or trusteeship
About Lille Catholic University
Lille Catholic University, a prominent academic institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university integrates expertise from various fields to foster the development of cutting-edge medical solutions. Its commitment to ethical standards and patient-centered approaches ensures that clinical trials conducted under its auspices are rigorous, scientifically sound, and aligned with the highest standards of care. By leveraging its extensive network of researchers, healthcare professionals, and resources, Lille Catholic University plays a vital role in contributing to the enhancement of medical knowledge and the improvement of patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, , France
Lomme, , France
Roubaix, , France
Arras, , France
Patients applied
Trial Officials
Sandy AMORIM
Principal Investigator
Onco-Hematology Department-Hôpital Saint Vincent de Paul-GHICL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported